ABL1 and acute lymphoblastic leukemia: Dasatinib is a multikinase inhibitor targeting ABL and Src family kinases, which is approved for use in imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) [15, 16].